This strategy was combined with applying an anti-CD38 nanobody to NK-92 cells in an ex vivo experiment to shift the balance of CD38 expression between effector and target cells, with findings of proportional promotion of MM cell death by shifting the target away from NK cells [130]. Here, CD38 is linked to Miyoshi myopathy.